Ozmosi | Repagermanium Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Repagermanium

Alternative Names: repagermanium
Clinical Status: Inactive
Latest Update: 2025-12-05
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Immunostimulant

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Dimerix Bioscience
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 4: COVID-19|Pneumonia

Phase 2: COVID-19

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT05122182

CLARITY 2

P2

Terminated

COVID-19

2022-08-15

2025-08-27

2015-002340-14

REMAP-CAP

P4

Unknown status

COVID-19|Pneumonia

2021-01-16

2025-07-07

Treatments